Folks stroll previous an indication for Novo Nordisk’s annual common assembly on the entrance to the venue in Copenhagen, Denmark, March 26, 2026.
Tom Little | Reuters
Novo Nordisk is partnering with OpenAI to “deliver new and higher therapy choices to sufferers sooner,” the Danish drugmaker stated Tuesday.
The partnership will allow Novo to higher use AI to research advanced datasets, establish promising new medication, and scale back the time it takes for a drugs to maneuver from the analysis stage to affected person use, the corporate stated in an announcement.
“There are thousands and thousands of individuals residing with weight problems and diabetes who want therapy choices, and we all know there are therapies nonetheless ready to be found that would change their lives,” stated Novo CEO Mike Doustdar. “Integrating AI in our on a regular basis work offers us the power to analyse datasets at a scale that was beforehand inconceivable, establish patterns we couldn’t see, and take a look at hypotheses sooner than ever.”
“AI is reshaping industries and in life sciences, it may assist folks dwell higher, longer lives,” stated OpenAI CEO Sam Altman.
The inventory jumped 2.8% shortly after the opening bell.
It comes as drugmakers are more and more turning to AI to enhance operations and prolonged processes. Whereas AI may uncover new remedies, specialists say that the business continues to be removed from leveraging the expertise’s full potential and extra instant advantages may come from utilizing it in different areas of drug growth. AI can, for instance, assist corporations within the time-consuming job of figuring out sufferers and websites for scientific trials.
“We’ve not heard the final of it but… when it comes to how scientific trials get designed and run, a number of it’s nonetheless very conventional, with sure factors the place AI is being leveraged,” Arthur D. Little associate Ben van der Schaaf, informed CNBC final month. “AI shouldn’t be an end-to-end element but.”
Novo’s newest transfer builds on its present AI initiatives, which additionally embrace a collaboration with Nvidia to make use of the Gefion sovereign AI supercomputer to “speed up drug discovery efforts by progressive AI use circumstances.” The businesses stated final yr that they intention to create custom-made AI fashions and brokers that Novo can use for early analysis and scientific growth.
Novo Nordisk is locked in a race with U.S. rival Eli Lilly for dominance within the profitable weight reduction market, through which it has misplaced its first-mover benefit. Novo is now attempting to claw again market share by its Wegovy capsule, launched in January, and next-generation medication.